Advertisement
Screener

Alkermes plc. (ALKS) Debt / Equity

Alkermes plc. Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Alkermes plc. debt/equity ratio for the quarter ending 2026-06-30 was 0.83.
  • Alkermes plc. debt/equity ratio for the quarter ending 2026-03-31 was 0.86.
  • Alkermes plc. debt/equity ratio for the quarter ending 2025-12-31 was 0.
  • Alkermes plc. debt/equity ratio for the quarter ending 2024-09-30 was 0.22, a 4.00% increase year-over-year.
  • Alkermes plc. debt/equity ratio for fiscal 2023 was 0.24, a 13.97% decline from fiscal 2022.
  • Alkermes plc. debt/equity ratio for fiscal 2022 was 0.28, a 5.68% increase from fiscal 2021.
  • Alkermes plc. debt/equity ratio for fiscal 2021 was 0.27, a 3.17% increase from fiscal 2020.
  • Alkermes plc. debt/equity ratio for fiscal 2020 was 0.26, a 0.93% increase from fiscal 2019.
Available history
2011-03-31 to 2026-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2026-06-300.83$1.5B$1.81B
2026-03-310.86$1.51B$1.75B
2025-12-310$0.00$1.82B
2024-09-300.22$288.82M$1.29B
2024-06-300.23$289.46M$1.28B
2024-03-310.23$290.1M$1.25B
2023-12-310.24$290.73M$1.2B
2023-09-300.21$291.37M$1.36B
2023-06-300.23$292M$1.28B
2023-03-310.29$292.64M$1.01B
2022-12-310.28$293.27M$1.04B
2022-09-300.28$293.9M$1.04B
2022-06-300.27$294.54M$1.08B
2022-03-310.27$295.17M$1.08B
2021-12-310.27$295.8M$1.11B
2021-09-300.27$296.44M$1.1B
2021-06-300.27$297.07M$1.1B
2021-03-310.28$297.7M$1.05B
2020-12-310.26$274.96M$1.07B
2020-09-300.25$275.51M$1.08B
2020-06-300.26$276.05M$1.06B
2020-03-310.26$276.59M$1.06B
2019-12-310.26$277.14M$1.09B
2019-09-300.26$277.68M$1.07B
2019-06-300.25$278.22M$1.09B
2019-03-310.25$278.77M$1.1B
2018-12-310.24$279.31M$1.17B
2018-09-300.24$279.85M$1.15B
2018-06-300.24$280.39M$1.16B
2018-03-310.24$280.93M$1.16B
2017-12-310.23$281.44M$1.2B
2017-09-300.24$281.99M$1.19B
2017-06-300.24$282.55M$1.2B
2017-03-310.23$283.11M$1.22B
2016-12-310.23$283.67M$1.21B
2016-09-300.24$285.58M$1.21B
2016-06-300.28$347.03M$1.24B
2016-03-310.28$348.49M$1.27B
2015-12-310.27$349.94M$1.31B
2015-09-300.26$353.22M$1.37B
2015-06-300.25$354.81M$1.4B
2015-03-310.25$356.39M$1.42B
2014-12-310.25$355.76M$1.4B
2014-09-300.27$359.55M$1.33B
2014-06-300.27$361.13M$1.35B
2014-03-310.27$362.71M$1.34B
2013-12-310.34$364.29M$1.07B
2013-09-300.36$365.87M$1.02B
2013-06-300.37$367.44M$981.94M
2013-03-310.39$369.01M$952.37M
2012-12-310.4$369.1M$919.94M
2012-09-300.42$370.6M$885.01M
2012-06-300.5$444.18M$882.49M
2012-03-310.52$444.46M$853.85M
2011-12-310.49$444.77M$904.85M
2011-09-300.49$444.18M$909.68M
2011-03-310$0.00$392.02M

Annual Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2023-12-310.24$290.73M$1.2B
2022-12-310.28$293.27M$1.04B
2021-12-310.27$295.8M$1.11B
2020-12-310.26$274.96M$1.07B
2019-12-310.26$277.14M$1.09B
2018-12-310.24$279.31M$1.17B
2017-12-310.23$281.44M$1.2B
2016-12-310.23$283.67M$1.21B
2015-12-310.27$349.94M$1.31B
2014-12-310.25$355.76M$1.4B
2013-12-310.34$364.29M$1.07B
2013-03-310.39$369.01M$952.37M
2012-03-310.52$444.46M$853.85M

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76